Investing in opportunities to improve health through innovation is a key driver of solutions for today’s most difficult healthcare problems. Astellas Venture Management (AVM) /Innovation Management (“AIM”) are interested in supporting early stage opportunities to advance the creation of human therapeutics. AVM/AIM will be presenting at Johnson and Johnson Innovation, JLABS on October 13th, 2015.

AVM is the venture group within Japan\’s one of largest pharmaceutical company, Astellas Pharma Inc. You may be familiar with some of AVM’s successful, local portfolio companies including Potenza Therapeutics, Raze Therapeutics, Verastem and Epizyme. With hundreds of millions in an evergreen fund, AVM is looking to invest in more private companies in the early stage drug discovery and platform technology across several therapeutic areas, including:

• Immunology and Inflammation, Urology, Oncology, Nephrology and Neuroscience
• Ophthalmology, Hearing Loss, Muscle disorder and Regenerative Medicine.

Also, AVM has another mission by AIM to execute early stage innovative collaborations with Academia and biotech companies. Recent collaboration deals include Mitobridge (Mitochondria diseases, drug discovery), Harvard Medical School (Retinitis Pigmentosa, Target identification), Proteostasis (Diseases caused by defects in protein folding, Drug discovery), DFCI (Oncology, drug discovery), Potenza (Immune oncology, drug discovery) and Kanyos Therapeutics (Autoimmune, drug discovery). AVM/AIM will provide equity and non-dilutive capitals to our portfolios and partners while actively looking for the new innovative opportunities.

Representatives from AVM/AIM will be in attendance to give an overview presentation on the company\’s key areas of interest and best practices when seeking funding. Following the presentation, don\’t miss this opportunity to network with fellow attendees and the AVM/AIM representatives during lunch. For those companies who apply online and receive approval, one-on-one meetings with AVM will provide a private forum to discuss your company.

Agenda:
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
12:00pm | Networking Lunch
12:30-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on September 15th.

AVM Participating Representatives:
Sakae Asanuma MBA, CFA | President & CEO, Astellas Venture Management read bio»
Takashi Futami | Associate Investment Director, Astellas Venture Management read bio»
Taro Masunaga, Ph.D. | Senior Investment Director, Astellas Venture Management read bio»
Hideaki Matsuoka, Ph.D. | Associate Investment Director, Astellas Venture Managementread bio»
Nobuaki Shindoh, Ph.D. | Associate Investment Director, Astellas Venture Managementread bio»

About Astellas Venture Management LLC:
Astellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to helping Astellas Pharma Inc. to achieve its strategic goals. The venture capital activity of AVM can be traced back to the year 1999. Through its strategic investments in private early-stage companies, the funds aim to forge relationships with Astellas Pharma, which may lead to larger collaborations in the future. AVM is able to provide portfolio companies with invaluable advice and assistance. Astellas Pharma Inc., the ultimate parent company of AVM, headquartered in Tokyo, was created on April 1, 2005 through the merger of two Japanese pharmaceutical companies. Astellas is actively engaged in business as an R&D-driven global pharmaceutical company with the business philosophy to \’Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.\’ With this philosophy, Astellas focuses on highly specialized therapeutic areas (categories) where there is a high degree of unmet medical needs.

About Innovation Management:
Innovation Management (\’AIM\’) is a newly established organization at Astellas Headquarter. AIM is a dedicated function for external collaboration to promote intake early stage innovation into Astellas R&D. AIM has closed several deals since its inception (Oct, 2013) including Mitokyne (mitochondrial disease drug discovery), Cancer Research UK (oncology target discovery), Harvard Medical School (ophthalmology target discovery), Dana-Farber Cancer Institute (oncology drug discovery) and Proteostasis (genetic disease drug discovery).

About Astellas Pharma Inc.:
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 18,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious Diseases, Oncology, Neuroscience and Diabetes Mellitus (DM) Complications and Kidney Diseases.

Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until October 12th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on September 15th. Your application will be reviewed and you will be notified of acceptance on September 29th, 2015. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Venue:
CIC Cambridge
Havana Room
1 Broadway
Cambridge, MA